Last updated: August 2025.
Big Eye Diagnostics was launched in 2022 with funding from the National Institutes of Health (NIH) as an offshoot of Drugs and Diagnostics for Tropical Diseases (DDTD) . Thanks to its technology and the dedication of its staff, Big Eye Diagnostics has rapidly positioned itself as a leader in rapid tests for Global Health, as evidenced by 6 distinct grants and contracts awarded by the Small Business Innovation Research (SBIR) program of the National Institute of Allergy and Infectious Diseases (NIAID) (See Table). Furthermore, Big Eye Diagnostics is also the recipient of subawards on consortia led by our non-profit sister company DDTD and generously underwritten by the Global Health Innovative Technology (GHIT) Fund. The combined funding exceeds $6 million, and has enabled us to deliver 3 tests firmly positioned to be commercialized starting in 2026. Additional tests are moving through the pipeline.
These successes are due to our ability to assemble world-class stakeholders in what are highly collaborative projects. Some of our most important and best-known partners are listed below:
World Health Organization
Centers Diseases for Control and Prevention
National Institute of Allergy and Infectious Diseases
The Carter Center
The Gates Foundation
We also work with other companies around the world, including Medical and Biological Laboratories (MBL), a leading antibody development Japanese company, and Advy, an Indian test manufacturer, and a number of academic or nonprofit institutions, including but not limited to The Task Force for Global Health (USA), Washington University (USA), Nagasaki University (Japan), Noguchi Memorial Institute for Medical Research (Ghana), Kenya Medical Research Institute (KEMRI), The University of Indonesia, and the University of Sciences, Malaysia.
